- Home
- SNDL vs PRTA Comparison
SNDL vs PRTA Comparison
Compare SNDL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDL
- PRTA
- Stock Information
- Founded
- SNDL 2006
- PRTA 2012
- Country
- SNDL Canada
- PRTA Ireland
- Employees
- SNDL N/A
- PRTA N/A
- Industry
- SNDL Pharmaceuticals and Biotechnology
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- SNDL Health Care
- PRTA Health Care
- Exchange
- SNDL Nasdaq
- PRTA Nasdaq
- Market Cap
- SNDL 651.1M
- PRTA 472.1M
- IPO Year
- SNDL 2019
- PRTA N/A
- Fundamental
- Price
- SNDL $2.68
- PRTA $8.20
- Analyst Decision
- SNDL
- PRTA Buy
- Analyst Count
- SNDL 0
- PRTA 10
- Target Price
- SNDL N/A
- PRTA $14.86
- AVG Volume (30 Days)
- SNDL 4.9M
- PRTA 1.2M
- Earning Date
- SNDL 07-31-2025
- PRTA 08-04-2025
- Dividend Yield
- SNDL N/A
- PRTA N/A
- EPS Growth
- SNDL N/A
- PRTA N/A
- EPS
- SNDL N/A
- PRTA N/A
- Revenue
- SNDL $692,339,389.00
- PRTA $10,341,000.00
- Revenue This Year
- SNDL $5.52
- PRTA N/A
- Revenue Next Year
- SNDL $4.09
- PRTA $389.77
- P/E Ratio
- SNDL N/A
- PRTA N/A
- Revenue Growth
- SNDL 3.54
- PRTA N/A
- 52 Week Low
- SNDL $1.15
- PRTA $4.32
- 52 Week High
- SNDL $2.74
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- SNDL 82.41
- PRTA 58.73
- Support Level
- SNDL $2.07
- PRTA $8.05
- Resistance Level
- SNDL $2.74
- PRTA $8.73
- Average True Range (ATR)
- SNDL 0.14
- PRTA 0.38
- MACD
- SNDL 0.05
- PRTA -0.05
- Stochastic Oscillator
- SNDL 92.50
- PRTA 47.62
About SNDL SNDL Inc.
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.